Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Blood (2017) 130 (Supplement 1): 891.

https://doi.org/10.1182/blood.V130.Suppl_1.891.891

Published: 2017

Journal Articles

Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1

Aaron D Goldberg, MD, Noushin Farnoud, PhD, Cody Goldberger, Minal Patel, BA, Christopher Famulare, MS, Juan Medina, Raajit K. Rampal, MD PhD, Ross L. Levine, MD, Ellin Berman, MD, Yanming Zhang, MD, Filiz Sen, MD, Elli Papaemmanuil, PhD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 2663.

https://doi.org/10.1182/blood.V130.Suppl_1.2663.2663

Published: 2017

Journal Articles

Activation Levels of b-Catenin Signaling in Osteoblasts Define a Threshold for the Development of Myeloid Neoplasia of Variable Severity

Ioanna Mosialou, PhD, Alvaro Cuesta-Dominiguez, PhD, Govind Bhagat, MD, Ellin Berman, MD, Azra Raza, MD, Stavroula Kousteni, PhD

Blood (2017) 130 (Supplement 1): 2946.

https://doi.org/10.1182/blood.V130.Suppl_1.2946.2946

Published: 2017

Journal Articles

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Aaron D Goldberg, MD, Troy Z. Horvat, PharmD, BCOP, Meier Hsu, MS, Sean M. Devlin, PhD, Bernadette M. Cuello, BSN, MSN, NP, RN, Ryan J. Daley, PharmD, BCOP, Amber C. King, PharmD, BCOP, Larry W Buie, PharmD, BCOP, FASHP, Jacob L Glass, MDPhD, Michael J. Mauro, MD, Eytan M. Stein, MD, Ellin Berman, MD, Virginia M. Klimek, MD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 1353.

https://doi.org/10.1182/blood.V130.Suppl_1.1353.1353

Published: 2017

Journal Articles

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Blood (2016) 128 (22): 5109.

https://doi.org/10.1182/blood.V128.22.5109.5109

Published: 2016

Journal Articles

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Gabriella Hobbs, MD, Rivka Litvin, Jihae Ahn, Anna Sophia Mckenney, Michael J. Mauro, MD, Martin S Tallman, MD, Ellin Berman, MD, Mark Lawrence Heaney, MD PhD, Ross L. Levine, MD, Raajit K. Rampal, MD, PhD

Blood (2015) 126 (23): 4075.

https://doi.org/10.1182/blood.V126.23.4075.4075

Published: 2015

Journal Articles

Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia

Masahiro Marshall Nakagawa, Aruna Kode, Sanil J Manavalan, Govind Bhagat, MD, Julie Teruya-Feldstein, MD, Azra Raza, MD, Ellin Berman, MD, Stavroula Kousteni

Blood (2015) 126 (23): 2551.

https://doi.org/10.1182/blood.V126.23.2551.2551

Published: 2015

Journal Articles

Foxo1 Expressed in Osteoblasts Promotes the Leukemogenic Properties of β-Catenin By Activating Notch Signaling

Aruna Kode, Ioanna Mosialou, Sanil J Manavalan, Julie Teruya Feldstein, Govind Bhagat, MD, Ellin Berman, MD, Stavroula Kousteni

Blood (2014) 124 (21): 2356.

https://doi.org/10.1182/blood.V124.21.2356.2356

Published: 2014

Journal Articles

High-Dose Cytarabine Monotherapy Versus Intermediate Or High-Dose Cytarabine In Combination With Other Agents As Second-Line Salvage Therapy In Patients With Acute Myeloid Leukemia Who Did Not Respond To Initial Induction Therapy

Thu Oanh T Dang, PharmD, BCOP, Patrick Hilden, MS, Sean M. Devlin, PhD, Raajit K. Rampal, M.D., Ph.D., Ross L. Levine, MD, Ellin Berman, MD, Virginia M. Klimek, M.D., Nelly G. Adel, PharmD, BCOP, BCPS, Martin S. Tallman, MD

Blood (2013) 122 (21): 2695.

https://doi.org/10.1182/blood.V122.21.2695.2695

Published: 2013

Journal Articles

Stem Cell Transplant Versus Chemotherapy in Older Adults with Acute Myelogenous Leukemia In First Remission

Ellin Berman, MD, Molly Maloy, MA, Sean M. Devlin, PhD, Esperanza B Papadopoulos, MD, Ann A. Jakubowski, MD, PhD

Blood (2013) 122 (21): 2146.

https://doi.org/10.1182/blood.V122.21.2146.2146

Published: 2013

Journal Articles

Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?

Ashwin Kishtagari, MBBS, Isaac Alexander Bowman, MD, Martin S. Tallman, MD, Dan Douer, MD, Ellin Berman, MD, Peter G. Maslak, M.D., Renier J Brentjens, MD, PhD, Eytan M Stein, MD

Blood (2013) 122 (21): 2740.

https://doi.org/10.1182/blood.V122.21.2740.2740

Published: 2013

Journal Articles

Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy

Elizabeth Halton, RN, MS, ANP, Dick Chung, BS, Kun Xiao, MS, MPH, Hilda Quintanilla, RN, MS, ANP, Christina Baldwin, RN, MS, ANP, Pamela Baird, RN, MS, ANP, Ellin Berman, MD, Renier J Brentjens, MD, PhD, Mark Heaney, MD, PhD, Joseph G. Jurcic, MD, Nicole Lamanna, MD, Todd L. Rosenblat, MD, Rana Kaplan, MD, Genovefa Papanicolaou, MD, Mark G. Frattini, MD, PhD

Blood (2012) 120 (21): 3556.

https://doi.org/10.1182/blood.V120.21.3556.3556

Published: 2012

Journal Articles

Outcome of Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia and Normal Cytogenetics (NC-AML) According to Presence of FLT-3 Internal Tandem Duplication (FLT-3ITD) At the Time of Diagnosis

Ellin Berman, MD, Ann A Jakubowski, MD, PhD, Molly Maloy, BA, Joseph G. Jurcic, MD, Suresh C. Jhanwar, PhD, Cyrus V. Hedvat, MD, PhD, Sergio Giralt, MD, Esperanza B. Papadopoulos, MD

Blood (2012) 120 (21): 2038.

https://doi.org/10.1182/blood.V120.21.2038.2038

Published: 2012

Journal Articles

High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL)

Nicole Lamanna, MD, Mark Weiss, MD, Ellin Berman, MD, Mark G. Frattini, MD, PhD, Mark Heaney, MD, PhD, Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Heather Landau, MD, Hanna Weissbrot, BA, Peter G. Maslak, M.D.

Blood (2012) 120 (21): 4293.

https://doi.org/10.1182/blood.V120.21.4293.4293

Published: 2012

Journal Articles

Leukemogenic Transformation of Hematopoietic Cells by Constitutive Activation of Canonical Wnt Signaling in Osteoblast Precursors

Aruna Kode, Sanil Manavalan, Ioanna Mossialou, Govind Bhagat, MBBS, Murty Vundavalli, Ronald DePinho, Julie Teruya-Feldstein, MD, Ellin Berman, MD, Stavroula Kousteni, PhD

Blood (2012) 120 (21): 509.

https://doi.org/10.1182/blood.V120.21.509.509

Published: 2012

Journal Articles

Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History

Jeffrey R Gardner, MBA, Kristina Knapp, Mark G. Frattini, MD, PhD, Nicole Lamanna, MD, Renier Brentjens, MD, PhD, Joseph G Jurcic, MD, Peter G. Maslak, M.D., Ellin Berman, MD, Mark Weiss, MD, David A. Scheinberg, MD, PhD, Mark Heaney, MD, PhD

Blood (2011) 118 (21): 1765.

https://doi.org/10.1182/blood.V118.21.1765.1765

Published: 2011

Journal Articles

Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center

Ellin Berman, MD, Cyrus V. Hedvat, MD, PhD, Joseph G. Jurcic, MD, Mark Heaney, MD, PhD, Peter G. Maslak, M.D., Renier Brentjens, MD, PhD, Nicole Lamanna, MD, Todd L. Rosenblat, MD, Mark G. Frattini, MD, PhD, Ann A Jakubowski, MD, PhD, Suresh Jhanwar, PhD

Blood (2011) 118 (21): 4433.

https://doi.org/10.1182/blood.V118.21.4433.4433

Published: 2011

Journal Articles

Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation.

Ellin Berman, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Thomas O'Hare, PhD, Christopher Eide, BS, Richard D. Press, MD, PhD, Brian J Druker, MD, Cyrus V. Hedvat, MD, PhD

Blood (2010) 116 (21): 3408.

https://doi.org/10.1182/blood.V116.21.3408.3408

Published: 2010

NARROW

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1

Activation Levels of b-Catenin Signaling in Osteoblasts Define a Threshold for the Development of Myeloid Neoplasia of Variable Severity

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia

Foxo1 Expressed in Osteoblasts Promotes the Leukemogenic Properties of β-Catenin By Activating Notch Signaling

High-Dose Cytarabine Monotherapy Versus Intermediate Or High-Dose Cytarabine In Combination With Other Agents As Second-Line Salvage Therapy In Patients With Acute Myeloid Leukemia Who Did Not Respond To Initial Induction Therapy

Stem Cell Transplant Versus Chemotherapy in Older Adults with Acute Myelogenous Leukemia In First Remission

Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?

Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy

Outcome of Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia and Normal Cytogenetics (NC-AML) According to Presence of FLT-3 Internal Tandem Duplication (FLT-3ITD) At the Time of Diagnosis

High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL)

Leukemogenic Transformation of Hematopoietic Cells by Constitutive Activation of Canonical Wnt Signaling in Osteoblast Precursors

Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History

Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center

Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only